United Kingdom - English - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 20 mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet: reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation

United Kingdom - English - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 40mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.

United Kingdom - English - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 10mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - nivolumab 10 mg/ml;  ;  ;   - concentrate for infusion - 100 mg/10ml - active: nivolumab 10 mg/ml       excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - nivolumab 10 mg/ml;  ;  ;   - concentrate for infusion - 40 mg/4ml - active: nivolumab 10 mg/ml       excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - lomustine 10mg - capsule - 10 mg - active: lomustine 10mg excipient: gelatin magnesium stearate mannitol opacode black s-1-27794 titanium dioxide - ceenu is indicated as palliative therapy to be employed in addition to other modalities, or in established combination therapy with other approved chemotherapeutic agents in the following: 1. brain tumours - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 100mg;   - film coated tablet - 100 mg - active: dasatinib 100mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 20mg;   - film coated tablet - 20 mg - active: dasatinib 20mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 50mg;   - film coated tablet - 50 mg - active: dasatinib 50mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 70mg;   - film coated tablet - 70 mg - active: dasatinib 70mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase